Lori Nottmeyer
Family · Mattoon, ILNPI 1700215928
Payments from drug & device makers
Across 354 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$809
- AstraZeneca$689
- Lilly USA, LLC$653
- Novartis$477
- Amgen$385
- Novo Nordisk$355
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,670100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $809 |
| AstraZeneca | 27 | $689 |
| Lilly USA, LLC | 49 | $653 |
| Novartis | 25 | $477 |
| Amgen | 27 | $385 |
| Novo Nordisk | 25 | $355 |
| Mylan Specialty L.p. | 16 | $264 |
| Pfizer | 12 | $198 |
| Boehringer Ingelheim | 8 | $157 |
| Bayer | 10 | $152 |
| Johnson & Johnson | 9 | $136 |
| Dexcom, Inc. | 7 | $134 |
| AbbVie | 8 | $132 |
| Exact Sciences | 5 | $108 |
| Phathom Pharmaceuticals, Inc. | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Daiichi Sankyo Inc. | 5 | $85 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Merck | 4 | $54 |
| Viatris Specialty LLC | 3 | $44 |
| Philips North America LLC | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Abbott | 2 | $33 |
| Radius Health, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$120
How this compares
$5,682 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 108 | $119,878 |
| JardianceEmpagliflozin | 99 | $92,562 |
| OzempicSemaglutide | 40 | $70,717 |
| EliquisApixaban | 51 | $59,129 |
| FarxigaDapagliflozin Propanediol | 31 | $43,821 |
| XareltoRivaroxaban | 40 | $34,056 |
| TrintellixVortioxetine Hydrobromide | 53 | $28,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $25,448 |
| WegovySemaglutide | 17 | $24,807 |
| EntrestoSacubitril/Valsartan | 20 | $22,120 |
| TrulicityDulaglutide | 11 | $15,438 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $15,152 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $14,275 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,786 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $653 | $135,316119 claims |
| Boehringer IngelheimJardiance, Glyxambi | $157 | $107,715112 claims |
| Novo NordiskOzempic, Wegovy | $355 | $95,52457 claims |
| PfizerEliquis | $198 | $59,12951 claims |
| AstraZenecaFarxiga, Brilinta | $689 | $51,19147 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $809 | $46,12579 claims |
| Johnson & JohnsonXarelto | $136 | $34,05640 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $92 | $28,49653 claims |
| NovartisEntresto | $477 | $22,12020 claims |
| MerckJanuvia | $54 | $6,23511 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $2,46515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Mattoon
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.